




Tandem Diabetes Care

AMF MEDICAL ACQUISITION OVERVIEW

DECEMBER 13, 2022



Safe Harbor

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this presentation constitute forward-looking statements, including, without limitation, statements about: the Company's future development of new diabetes-related products and services, the Company's advancement of new insulin pump offerings, including its continued development and introduction of a rechargeable patch pump that features pre-filled insulin cartridges, the ability of the Company to successfully obtain FDA approval for its patch pump, and the expected time-to-market of the patch pump and its ability to influence channel expansion and increase customer access. Additional forward-looking statements relate to the timing and amount of any future earnout payments. These statements are subject to numerous risks and uncertainties, including the Company's ability to innovate and manage growth, the Company's ability to successfully integrate AMF Medical's patch pump products and designs into the Company's diabetes-related products and services, the Company's ability to successfully complete the development of the patch pump and related manufacturing processes and secure regulatory approvals for a new patch pump, market acceptance of the Company's existing products and products under development by physicians and people with diabetes, the potential that newer products, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the Company's products obsolete or less desirable, as well as other risks identified in our most recent Annual Report on Form 10-K, Annual Report on Form 10-Q, as well as in the other reports we file with the Securities and Exchange Commission. In addition, new risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. Estimates and forward-looking statements speak only as of the date they were made, and, except to the extent required by law, we undertake no obligation to update or review any estimate and forward-looking statement because of new information, future events or other factors.


NON-GAAP FINANCIAL MEASURES

Discussion accompanying this presentation may reference certain non-GAAP financial measures, including, without limitation, non-GAAP sales and EBITDA. Non-GAAP sales are determined in accordance with GAAP, adjusted for the impact of the Tandem Choice technology access program which launched in September 2022. The accounting treatment for Tandem Choice has a high degree of complexity, initially requiring the deferral of some portion of sales for shipments of eligible pumps. Adjusted EBITDA margin is a non-GAAP financial measure defined as net income (loss) excluding income taxes, interest and other non-operating items and depreciation and amortization. Adjusted EBITDA further adjusts for the change in fair value of common stock warrants non-cash stock-based compensation expense, the impact of the Tandem Choice technology access program and the acquired in-process research and development. This definition of Adjusted EBITDA may differ from similar measures used by other companies, even when similar terms are used to identify such measures. These non-GAAP measures have not been calculated in accordance with GAAP and should not be considered an alternative for measures prepared in accordance with GAAP. The presentation of non-GAAP information is not meant to be considered superior to, in isolation from or as a substitute for results prepared in accordance with GAAP. We believe these non-GAAP financial measures enhance investors' overall understanding of our current financial performance and our prospects for the future.


TRADEMARKS

©2022 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, t:slim X2, Control-IQ, micro-delivery, t:connect, source, touch simplicity, positively different and our logos are trademarks, registered trademarks, and/or the subject of a pending trademark application in the U.S. and other territories worldwide. All other trademarks and copyrights are the property of their respective owners.

Portfolio Approach for a Highly Segmented Market



Expanding Our Family of Delivery Devices



t:slim X2 is commercially available. Mobi is under review by the U.S. Food & Drug Administration. All other devices are under development and subject to future regulatory submission and clearance.



The Sigi Patch Pump, by **amf** medical



*The Sigi™ Patch Pump is under development
and not commercially available.*



Strategic Rationale

Expands addressable market opportunity, which is vastly underpenetrated today

- + U.S. type 1 pump penetration: ~35%¹
- + OUS type 1 pump penetration in Tandem-served markets: ~12%¹
- + U.S. type 2 penetration: ~5%¹
(less OUS based on hospital system practices)

Accelerates our longer-term patch pump pipeline objective

- + Reduces development risk
- + Provides differentiated feature set offering

Achieves environmental product objectives

- + Minimizes generation of electronic waste
- + Emphasizes sustainability

Provides pathway for channel expansion and increased customer access

- + Additional opportunity to pursue pharmacy channel offering
- + Business model optimization



About AMF Medical

- + Based in St. Sulpice, Switzerland
 - Maintaining AMF Medical's Swiss business operations post-close
- + Experienced, mission-driven team
 - Approximately 20 employees
 - Diabetes device, life sciences, space and watch industry backgrounds
 - Disciplined focus on design for manufacturability
- + Sigi™ received Breakthrough Device Designation from the FDA in November 2021



ANTOINE BARRAUD, PHD
Co-CEO and Co-founder



PIM VAN WESEL
Co-CEO



Summary Financial Terms of Agreement

- + **Q3 2022:** Strategic investment of CHF 8.0 million paid
- + **Due at closing:** Cash payment of CHF 62.4 million
 - Anticipated close: January 2023
- + **Additional contingent earnout payments:** up to CHF 129.6 million
 - Earnout breakdown:
 - Up to CHF 38.4 million: Achievement of certain development milestones
 - Up to CHF 91.2 million: FDA clearance of ACE Pump
 - Payments are scaled based on timeline to successful completion
 - Anticipated to be paid over two to five years following closing



Key Sigi Features In Development


- + Low-profile, ergonomic design
- + Pre-filled cartridges
- + Designed with a focus on ease-of-use
- + Rechargeable
- + Extended wear options for on-body infusion site
- + Automated Insulin Dosing (AID) compatible



The Sigi™ Patch Pump is under development and not commercially available.



About Sigi



Key M&A Criteria

- + Addressable market expansion
- + Enhanced user experience
- + Market access
- + Business model optimization
- + Leverage opportunities:
 - Salesforce at the same call point
 - Data management platform
 - Customer service


Delivering on our mission to improve the lives of people with diabetes.



Conclusion

- + AMF Medical's proprietary and disruptive insulin delivery solution is expected to:
 - Expand Tandem's type 1 and type 2 addressable market opportunities
 - Accelerate time-to-market for a patch pump in Tandem's portfolio
 - Further Tandem's sustainability objectives by offering an additional pump that minimizes the generation of electronic and battery waste
 - Provide a pathway for channel expansion and increased customer access
- + Strong balance sheet appropriately leveraged for transaction
 - Long-term potential value justifies the near-term impact to profitability
- + Positions Tandem to further drive growth through innovation, while improving the lives of people with diabetes

 **Life with diabetes... easier!**



The Sigi™ Patch Pump is under development and not commercially available.





Q&A